Current Treatment Options in Neurology最新文献_第2页

Multicolumn Spinal Cord Stimulation for Chronic Back and Leg Pain in Patients with Failed Back Surgery Syndrome: A Systematic Review and Meta-Analysis 多柱脊髓刺激治疗背部手术失败综合征患者的慢性背痛和腿痛：系统回顾与元分析

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-08-13 DOI: 10.1007/s11940-024-00807-5

Hany Atwan, Ibrahim Serag, Mohamed Abouzid

{"title":"Multicolumn Spinal Cord Stimulation for Chronic Back and Leg Pain in Patients with Failed Back Surgery Syndrome: A Systematic Review and Meta-Analysis","authors":"Hany Atwan, Ibrahim Serag, Mohamed Abouzid","doi":"10.1007/s11940-024-00807-5","DOIUrl":"https://doi.org/10.1007/s11940-024-00807-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>Failed Back Surgery Syndrome (FBSS) presents a formidable challenge, marked by the persistence of chronic lower back pain and leg pain despite undergoing surgical interventions. Multicolumn spinal cord stimulation (m-SCS) has recently emerged as a promising therapeutic strategy for addressing the pain associated with FBSS. This meta-analysis aims to study the efficacy of m-SCS in mitigating chronic back and leg pain among patients with FBSS.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A comprehensive search of electronic databases (PubMed, Web of Science, Scopus, Cochrane Library) was conducted to identify relevant studies published up to October 25th, 2023. Inclusion criteria encompassed randomized controlled trials and cohort studies evaluating the outcomes of m-SCS in patients with FBSS. The primary outcome measured was the Visual Analog Scale (VAS) score for low back and leg pain at baseline, six months, and 12 months.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of eight studies, including 271 patients, were analyzed. At six months, there was a statistically significant reduction in the VAS scores for low back pain (MD, 4.76; 95% CI, 3.78 to 5.74) and leg pain (MD, 4.41; 95% CI, 2.93 to 5.90) compared to baseline. Similarly, at 12 months, there was a statistically significant reduction in the VAS scores for low back pain (MD, 4.77; 95% CI, 4.34 to 5.20) and leg pain (MD, 2.78; 95% CI, 0.72 to 4.85) compared to baseline.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>m-SCS effectively manages chronic back and leg pain in FBSS patients, providing sustained pain relief. Studies with more extended follow-up periods and qualitative analysis for the functional outcomes and overall improvement for the patients with FBSS are recommended.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"18 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic Testing for Epilepsy: A User Guide 癫痫基因检测：用户指南

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-08-02 DOI: 10.1007/s11940-024-00806-6

Adelyn Beil, Mallory Wagner, Jill Nulle, Megan Friedli, Louis T. Dang, Tong Pan

{"title":"Genetic Testing for Epilepsy: A User Guide","authors":"Adelyn Beil, Mallory Wagner, Jill Nulle, Megan Friedli, Louis T. Dang, Tong Pan","doi":"10.1007/s11940-024-00806-6","DOIUrl":"https://doi.org/10.1007/s11940-024-00806-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>About 30% of epilepsy cases have an underlying genetic etiology. Despite rapid progress with understanding the genetic underpinnings of epilepsy and with gene-specific treatments for epilepsy, many barriers for clinicians to send genetic testing remain. This review aims to provide clinicians with a practical approach to genetic testing for epilepsy.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Incorporation of genetic counselors into neurology practices is a useful model for supporting providers to implement proper recommendations. Selecting the appropriate genetic test for epilepsy involves prioritizing patients’ informed consent and evaluating diagnostic yield, cost-effectiveness, and turnaround time following certain algorithms, with exome/genome sequencing as first-tier options, and multigene epilepsy panel as a more accessible alternate for resource-limited situations. Result interpretation should be conducted on a case-by-case basis, and should include interpretation of the results, changes in clinical management, inheritance risks, testing of family members, and discussion of additional testing if needed.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>We provide a comparative assessment of the yield of genetic tests for epilepsy, with possible test outcomes and practical considerations for the clinical decision-making process. Continued research and integration of cutting-edge approaches will expand our understanding of genetics in epilepsy and improve clinical outcomes for individuals with epilepsy.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"5 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141882263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Key Treatment Issues for Epilepsy in the Context of Autism Spectrum Disorder 自闭症谱系障碍背景下的癫痫治疗关键问题

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-07-19 DOI: 10.1007/s11940-024-00804-8

D. Dilara Ertenu, Julianne Sohn, Jay A. Salpekar

{"title":"Key Treatment Issues for Epilepsy in the Context of Autism Spectrum Disorder","authors":"D. Dilara Ertenu, Julianne Sohn, Jay A. Salpekar","doi":"10.1007/s11940-024-00804-8","DOIUrl":"https://doi.org/10.1007/s11940-024-00804-8","url":null,"abstract":"<p>The relationship between epilepsy and autism spectrum disorder (ASD) is complex and multifaceted. The prevalence of ASD in children with epilepsy is notably high, particularly in those with developmental epileptic encephalopathies (DEEs). DEEs, characterized by co-occurring epileptic activity and developmental impairments, often overlap with ASD, further complicating clinical presentations of difficulties in motor skills, language, social interaction, and adaptive behavior. The co-occurrence may be attributable to shared pathophysiological mechanisms, common genes, pre- and peri-natal risk factors, and disruptions in neurotransmitter pathways, particularly the glutamatergic and GABAergic systems. The presence of ASD in epilepsy profoundly impacts treatment choices and necessitates a careful balance between seizure control and behavioral management. Effective management of epilepsy in individuals with ASD requires a comprehensive approach, including anti-seizure medications (ASMs) like valproate and levetiracetam, which may address both seizures and behavioral issues. EEG monitoring is crucial for accurate diagnosis, distinguishing between epileptic and ASD-related behaviors. This review carefully details the overlap and physiological underpinnings of both disorders and underscores the necessity of tailored therapeutic approaches to medical care, emphasizing a multidisciplinary strategy to optimize outcomes.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"22 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141745709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Diagnosis and Management of Progressive Corticobasal Syndrome 更正：进行性皮质基底综合征的诊断与管理

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-07-12 DOI: 10.1007/s11940-024-00805-7

Claire Delpirou Nouh, Kyan Younes

引用次数: 0

Efficacy and Safety of Atogepant for Preventing Chronic and Episodic Migraines: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 阿托格潘预防慢性和发作性偏头痛的有效性和安全性：随机对照试验的系统回顾和元分析

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-07-12 DOI: 10.1007/s11940-024-00803-9

Lucca Moreira Lopes, Artur Menegaz de Almeida, Eric Pasqualotto, Renan Yuji Ura Sudo, Marianna Gerardo Hidalgo Santos Jorge Leite, Maria Eduarda Cavalcanti Souza, Francisco Cezar Aquino de Moraes, Victória Morbach Siebel, Nathália Figueiredo

{"title":"Efficacy and Safety of Atogepant for Preventing Chronic and Episodic Migraines: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Lucca Moreira Lopes, Artur Menegaz de Almeida, Eric Pasqualotto, Renan Yuji Ura Sudo, Marianna Gerardo Hidalgo Santos Jorge Leite, Maria Eduarda Cavalcanti Souza, Francisco Cezar Aquino de Moraes, Victória Morbach Siebel, Nathália Figueiredo","doi":"10.1007/s11940-024-00803-9","DOIUrl":"https://doi.org/10.1007/s11940-024-00803-9","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Calcitonin gene-related peptide (CGRP) pathway modulators, such as atogepant, represent a novel therapeutic option for the treatment of migraines. We performed a systematic review and meta-analysis to evaluate the effects of 12-week treatment with atogepant compared with placebo in patients with migraine.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>A total of four RCTs and 3,140 patients were included, of whom 2,306 were prescribed atogepant. Compared with placebo, atogepant significantly reduced monthly migraine days (WMD -1.27; 95% CI -1.71,-0.83; p < 0.01), days with acute medication use (WMD -1.49; 95% CI -1.96,-1.02; p < 0.01), and monthly headache days (WMD -1.53; 95% CI -1.90,-1.15; p < 0.01). In the subgroup analysis of those outcomes, overall results were similar between groups. There was a significant increase in nausea (RR 2.23; 95% CI 1.43, 3.48; p < 0.01) and constipation (RR 3.57; 95% CI 1.62, 7.89; p < 0.01) in the atogepant-treated group. There were no significant differences in nasopharyngitis, upper airway infection, urinary tract infection, fatigue, serious adverse events, and discontinuation of treatment due to adverse events.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>This meta-analysis of RCTs suggests that atogepant is effective in the reduction of migraine episodes among patients with migraine headaches, albeit with an increase in nausea and constipation relative to placebo.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"55 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141612990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanical Thrombectomy for Acute Ischemic Stroke: Current State and Future Directions 急性缺血性脑卒中的机械取栓术：现状与未来方向

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-07-11 DOI: 10.1007/s11940-024-00796-5

Amol M. Mehta, Shashvat M. Desai, Ashutosh P. Jadhav

{"title":"Mechanical Thrombectomy for Acute Ischemic Stroke: Current State and Future Directions","authors":"Amol M. Mehta, Shashvat M. Desai, Ashutosh P. Jadhav","doi":"10.1007/s11940-024-00796-5","DOIUrl":"https://doi.org/10.1007/s11940-024-00796-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>This review summarizes significant advancements in mechanical thrombectomy (MT) to treat acute ischemic stroke after the pivotal DAWN (Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention with Trevo) and DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3) trials. We focus on the evolution of MT over the past 5 years, highlighting critical trials and their implications for clinical practice.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>Recent randomized clinical trials have underscored the efficacy of MT in improving functional outcomes and reducing mortality in acute ischemic stroke patients with large ischemic cores and basilar artery occlusion. The field anticipates further randomized data that could expand MT indications to include patients with low stroke severity, preexisting disabilities, medium vessel occlusion, and those presenting beyond 24 h from stroke onset. Emerging data support simplified imaging paradigms for patient selection, enhanced pre-hospital triage protocols to expedite recanalization times, and the exploration of neuroprotective agents and intraarterial thrombolytics to improve post-MT outcomes.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Mechanical thrombectomy has solidified its role as a highly effective treatment for stroke, with indications for its use continuing to broaden. Future challenges include further expanding MT indications to encompass a wider patient population, optimizing the MT care pathway, enhancing post-MT recovery, and improving access to this critical intervention.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"139 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141587682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of Obstructive Sleep Apnea on Cognition: A Focus on Decision-Making 阻塞性睡眠呼吸暂停对认知的影响：关注决策

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-07-08 DOI: 10.1007/s11940-024-00800-y

Elettra Cini, Roberto Salabelle, Maria Salsone, Nicola Canessa, Andrea Galbiati, Luigi Ferini-Strambi

{"title":"The Effect of Obstructive Sleep Apnea on Cognition: A Focus on Decision-Making","authors":"Elettra Cini, Roberto Salabelle, Maria Salsone, Nicola Canessa, Andrea Galbiati, Luigi Ferini-Strambi","doi":"10.1007/s11940-024-00800-y","DOIUrl":"https://doi.org/10.1007/s11940-024-00800-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>In this review, we discuss the impact of Obstructive Sleep Apnea (OSA), a sleep-related breathing disorder characterized by repetitive episodes of complete cessation of airflow or decreases in airflow due to upper airway obstruction leading to sleep fragmentation, on decision-making. We will first delve into how OSA affects cognition and executive functions, which are pivotal for optimal decision-making. Subsequently, we will explore its impact on decision-making itself. Unveiling these dynamics is crucial to better understand their implications on patients’ well-being, aging, daily functioning, and treatment adherence.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Previous research suggests that factors such as intermittent hypoxemia and sleep fragmentation may contribute to excessive daytime sleepiness, which is indeed the most prevalent daytime symptom observed in OSA. These factors also impact several neuropsychological domains, such as attention, memory, and executive functions. However, little is known about how OSA affects a complex cognitive domain like decision-making.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Interestingly, compared to control subjects, OSA patients showed impaired decision-making, with the degree of the impairment associated with the severity of the disorder. The heterogeneity of results is ascribable to the utilization of different tasks across studies and the inclusion of patients with different severities of OSA. Future studies are expected to address the neuro-cognitive mechanisms contributing to decision-making impairments in OSA, the precursors of individual differences, and the efficacy of targeted interventions. Longitudinal studies are required to unveil the trajectory of decision-making deficits and their effects on clinical outcomes and quality of life in OSA patients.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"25 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141572668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis and Management of Progressive Corticobasal Syndrome 进行性皮质基底综合征的诊断与管理

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-06-25 DOI: 10.1007/s11940-024-00797-4

Claire Delpirou Nouh, Kyan Younes

{"title":"Diagnosis and Management of Progressive Corticobasal Syndrome","authors":"Claire Delpirou Nouh, Kyan Younes","doi":"10.1007/s11940-024-00797-4","DOIUrl":"https://doi.org/10.1007/s11940-024-00797-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>The purpose of this review is to discuss the clinical, radiological, and neuropathological heterogeneity of corticobasal syndrome (CBS), which can complicate the determination of underlying etiology and lead to inaccurate treatment decisions. Though the most common diagnosis is corticobasal degeneration (CBD), the spectrum of underlying pathologies expands beyond CBD and can overlap with other neurodegenerative diseases and even the neuroimmunology field. We will review possible clinical presentations and cues that can point towards the etiology. We will also discuss the most recent available biomarkers to facilitate a more accurate diagnosis. Additionally, we will examine current and future potential therapeutic options.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>The range of available fluid and neuroimaging biomarkers is increasing and some are already being used in clinical practice. While the treatment of neurodegenerative diseases is largely aimed at managing symptoms, early detection and accurate diagnosis are crucial for initiating early management and enrollment in clinical trials. The recent approval of a disease-modifying therapy for Alzheimer's disease (AD) has raised hopes for the development of more therapeutic options for other proteinopathies. Several candidates are currently being studied in clinical trial pipelines, particularly those targeting tau pathology.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Recent advancements in understanding the genetic and neuropathological diversity of CBS, along with the promising development of fluid and imaging biomarkers, are driving clinical trial research forward, instilling optimism for creating more effective disease-modifying treatments for brain proteinopathies.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"16 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141501610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Endovascular Treatments in Neuro-Ophthalmology 当前神经眼科的血管内治疗方法

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-06-24 DOI: 10.1007/s11940-024-00799-2

Johanna Yun, Marc Dinkin

{"title":"Current Endovascular Treatments in Neuro-Ophthalmology","authors":"Johanna Yun, Marc Dinkin","doi":"10.1007/s11940-024-00799-2","DOIUrl":"https://doi.org/10.1007/s11940-024-00799-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Endovascular interventions have dramatically contemporized neuro-ophthalmological care in the twenty-first century. This review summarizes interventions with their advantages and disadvantages for intracranial aneurysms, carotid cavernous fistulas (CCF), and idiopathic intracranial hypertension (IIH), all of which are encountered in routine neuro-ophthalmologic practice.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>There is a paucity of randomized, controlled trials comparing therapies for intracranial aneurysms, CCFs and IIH, specifically for neuro-ophthalmic outcomes. Flow diversion is a favorable treatment for intracranial aneurysms compressing the optic nerve and other cranial nerves. Coil embolization remains the most common treatment for cavernous carotid fistulas with low rates of secondary cranial neuropathy. Flow diversion has recently been explored in both direct and Type B indirect carotid cavernous fistulas. Lastly, for IIH, venous sinus stenting has become a popular alternative to surgical shunting, though, as with shunts, there is a risk of stent-related complications.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Endovascular therapy has evolved for each vascular disease and continues to transform to meet the needs of its patients. There are advantages and disadvantages to each type of treatment – endovascular or surgical – and the decision is patient-, surgeon-, and institution-dependent.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"37 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141501465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sleep Disorders in Adults with Intellectual Disability: Current Status and Future Directions 智障成人的睡眠障碍：现状与未来方向

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-06-19 DOI: 10.1007/s11940-024-00801-x

Bhathika Perera, David O’Regan

{"title":"Sleep Disorders in Adults with Intellectual Disability: Current Status and Future Directions","authors":"Bhathika Perera, David O’Regan","doi":"10.1007/s11940-024-00801-x","DOIUrl":"https://doi.org/10.1007/s11940-024-00801-x","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>We performed a narrative review of the current knowledge in epidemiology, mechanisms, clinical presentation, and treatment of sleep disorders in adults with intellectual disability.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Adults with Intellectual disability face significant mental and physical health disparities, including in sleep medicine. Despite sleep disorders having been identified as adversely affecting the health and quality of life of both adults with intellectual disabilities and their caregivers, the evidence base for assessment, diagnosis and treatment in this population remains under developed when compared to that of the general population. This review summarises the existing literature on insomnia, sleep disordered breathing, and other common sleep disorders in adults with intellectual disability. Emphasising the existing gaps in our understanding of sleep disorders in adults with intellectual disabilities, we propose strategies to address and mitigate these gaps.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Sleep disorders are common, yet frequently ignored in adults with intellectual disabilities. To address sleep health inequality gaps, future research should adopt tailored approaches, considering the heterogeneity within the intellectual disability population, including stratification by aetiology and health comorbidities. This is essential to improve the diagnostic accuracy and treatment of sleep disorders in adults with intellectual disability.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"64 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141501611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0